Timber Pharmaceuticals Announces Presentation at 2021 H.C. Wainwright Global Life Sciences Conference
Timber Pharmaceuticals (TMBR) announced that CEO John Koconis will present a corporate overview at the virtual 2021 H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. The presentation will be available for on-demand viewing starting March 9 at 7:00 AM EST. Koconis and CFO Joe Luchese will also hold one-on-one investor meetings during the event. Timber focuses on developing treatments for rare dermatologic diseases, with a current emphasis on non-systemic therapies for conditions like congenital ichthyosis and facial angiofibromas.
- Participation in a prominent industry conference, potentially increasing visibility with investors.
- Focus on rare dermatologic diseases may position Timber favorably in a niche market.
- None.
WOODCLIFF LAKE, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that Timber’s Chief Executive Officer John Koconis will present a corporate overview at the virtual 2021 H.C. Wainwright Global Life Sciences Conference being held on March 9-10, 2021.
Timber’s presentation will be available to registered conference attendees for on-demand viewing beginning March 9, 2021 at 7:00AM EST via the virtual conference link.
Mr. Koconis and Joe Luchese, Chief Financial Officer, will also participate in one-on-one investor meetings with registered conference attendees throughout the conference.
About Timber Pharmaceuticals, Inc.
Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases. The Company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles. The Company is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas (FAs) in tuberous sclerosis complex (TSC), and scleroderma. For more information, visit www.timberpharma.com.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, intellectual property rights, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential, "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's Form 10-Q filed on August 18, 2020 and its other filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
For more information, contact:
Timber Pharmaceuticals, Inc.
John Koconis
Chief Executive Officer
jkoconis@timberpharma.com
Investor Relations:
Stephanie Prince
PCG Advisory
(646) 863-6341
sprince@pcgadvisory.com
Media Relations:
Adam Daley
Berry & Company Public Relations
(212) 253-8881
adaley@berrypr.com
FAQ
When will Timber Pharmaceuticals present at the H.C. Wainwright Global Life Sciences Conference?
Who is presenting the corporate overview for Timber Pharmaceuticals?
What is the focus of Timber Pharmaceuticals?
What specific diseases is Timber Pharmaceuticals targeting?
